A Phase 2a Randomized, Single-blind, Placebo-controlled Pilot Study to Evaluate the Impact of Cariprazine (1.5mg) on Cocaine Use in OUD-CocUD Patients on Buprenorphine-naloxone.
Latest Information Update: 14 May 2024
At a glance
- Drugs Cariprazine (Primary) ; Buprenorphine/naloxone
- Indications Cocaine-related disorders; Opioid-related disorders
- Focus Therapeutic Use
- 07 May 2024 Planned End Date changed from 1 Apr 2024 to 31 Jan 2025.
- 07 May 2024 Planned primary completion date changed from 1 Apr 2024 to 31 Oct 2024.
- 11 Jul 2022 Planned initiation date changed from 1 Jun 2022 to 1 Jul 2022.